Tinea Capitis: Ringworm of the Scalp - Fungal Treatment Guide

Tinea capitis, commonly known as ringworm of the scalp, is a common dermatophyte infection primarily affecting children aged 3-14 years, though prevalence in adults and adolescents continues rising. This fungal infection presents with scaling, erythema, and hair loss, potentially causing inflammatory responses ranging from mild superficial desquamation to severe kerion formation with purulent drainage and permanent scarring alopecia. Accurate identification of causative species is essential, as treatment duration and efficacy vary significantly.

Epidemiology and Causative Organisms

Tinea capitis accounts for 3-5% of all dermatologic consultations in pediatric populations. Microsporum canis and Microsporum audouinii historically dominated, but Trichophyton tonsurans now represents 80-90% of cases in North America, while Microsporum canis persists in European populations. Trichophyton mentagrophytes, T. violaceum (Asia and Middle East), and T. schoenleinii (Mediterranean and African regions) maintain regional significance.

Dermatophytes colonize the scalp through direct contact with infected individuals, animals (particularly cats and dogs for M. canis), or contaminated fomites including combs, brushes, headgear, and bedding. Warm, moist scalp environments and minor hair-follicle trauma increase susceptibility. Risk factors include poor socioeconomic conditions, crowded living situations, poor hygiene, recent antibiotic use, and immunosuppression.

Clinical Presentations

Non-inflammatory (Black Dot) Ringworm: T. tonsurans classically presents with diffuse scaling and patchy alopecia with "black dot" appearance from broken hairs at the scalp surface. Inflammation is minimal, and pruritus mild. This presentation comprises 90% of North American tinea capitis.

Inflammatory (Gray Patch) Ringworm: M. canis and M. audouinii produce more prominent erythema with grayish-white scaling and easily pluckable, broken hairs. Occipital and temporal distributions are common.

Kerion: Severe inflammatory response characterized by pustules, crusting, exudation, and potential abscess formation. Lymphadenopathy, particularly occipital and cervical, accompanies kerion development. Kerions represent host immune response to infection rather than treatment failure, and appropriate systemic therapy remains indicated despite severe appearance. Permanent scarring alopecia occurs in 20-30% of untreated kerions.

Favus: T. schoenleinii infection presents with scutula (yellow cup-shaped crusts) atop follicles. This rare presentation in developed nations remains common in developing countries and often results in permanent alopecia.

Diagnostic Methods

Potassium hydroxide (KOH) mount preparations of plucked hairs (not cut) and scales are simple initial screening, though sensitivity is only 40-60%. Calcofluor white staining improves visualization under fluorescence microscopy. Fungal culture on Sabouraud dextrose agar or specialized dermatophyte media identifies species, requiring 2-4 weeks incubation at 25-30°C. Dermatophyte test medium (DTM) provides faster organism identification through color change from yellow to red, though morphologic differentiation remains difficult.

Wood's lamp examination has limited utility; most T. tonsurans infections show no fluorescence, while M. canis may exhibit faint blue-green luminescence. Culture remains the gold standard for species identification and antifungal susceptibility testing.

Treatment Protocols

Systemic Antifungals: Griseofulvin microsize 20-25 mg/kg/day (maximum 1000 mg/day) for 6-12 weeks remains the traditional standard, though clinical response is declining with emerging griseofulvin-resistant strains. Terbinafine 4-6 mg/kg/day (maximum 250 mg/day) for 4 weeks shows equivalent or superior efficacy, particularly for T. tonsurans, with 90-95% cure rates. Itraconazole pulsed dosing (5 mg/kg/day for 1 week per month × 2-3 months) or continuous dosing (5 mg/kg/day × 4 weeks) achieves 85-95% cure rates. Fluconazole 6 mg/kg/day × 3-6 weeks shows efficacy, though less extensive clinical data exists compared to terbinafine.

Adjunctive Topical Therapy: Antifungal shampoos (selenium sulfide 2.5%, zinc pyrithione 1-2%, ketoconazole 2%) used twice weekly reduce spore shedding and transmission but are inadequate monotherapy. These serve to minimize contagion among close contacts.

Treatment Modifications: Kerions benefit from adjunctive oral corticosteroids (prednisone 1 mg/kg/day maximum 50 mg for 2 weeks) to reduce severe inflammation and minimize permanent scarring risk.

Relapse and Resistance

Inadequate treatment duration accounts for most relapses. Griseofulvin resistance in T. tonsurans has increased from <5% (2000s) to 15-25% (2020s), necessitating terbinafine preference. Topical monotherapy relapses occur in 30-40% of cases due to poor scalp penetration. Baseline antifungal susceptibility testing should guide therapy in treatment-refractory cases.

FAQ

Q: Is tinea capitis contagious to other children and adults?
A: Yes. Most dermatophytes transmit through direct contact or fomites. Children should be isolated from school/daycare until systemic therapy has been administered for 4 weeks. Animal-source dermatophytes (M. canis) have zoonotic transmission risk.

Q: How long does treatment typically last?
A: Systemic antifungal therapy ranges from 4 weeks (terbinafine for T. tonsurans) to 12 weeks (griseofulvin for difficult cases). Clinical improvement appears within 2-4 weeks, but full resolution requires complete therapy duration.

Q: Can tinea capitis cause permanent baldness?
A: Most cases result in temporary telogen effluvium with hair regrowth within 3-6 months. Untreated kerions or favus cases may cause permanent scarring alopecia affecting 10-30% of hair follicles in affected areas.

Q: What about household contacts and animals?
A: Close human contacts should be examined; asymptomatic carriage occurs. If pets (particularly cats) are infected with M. canis, veterinary treatment is necessary to prevent reinfection.

References